A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study

Apixaban Dosing Patterns Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation Receiving Dialysis: A Retrospective Cohort Study

(2022) James B. Wetmore et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Direct Oral Anticoagulants vs. Warfarin in Hemodialysis Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis

(2022) Sohil Elfar et al.   Frontiers in Cardiovascular Medicine

Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation

(2022) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial

(2022) Sean D. Pokorney et al.   CIRCULATION

Safety of apixaban compared to warfarin in hemodialysis patients: Do antiplatelets make a difference?

(2021) Filip Ionescu et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation

(2021) Jan Steffel et al.   EUROPACE

Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial

(2021) An S. De Vriese et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Dialysis

(2020) Toshiki Kuno et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Apixaban versus No Anticoagulation in Patients Undergoing Long-Term Dialysis with Incident Atrial Fibrillation

(2020) Thomas A. Mavrakanas et al.   Clinical Journal of the American Society of Nephrology

2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)

(2020) Gerhard Hindricks et al.   EUROPEAN HEART JOURNAL

Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis

(2020) Lai-Chu See et al.   CARDIOVASCULAR DRUGS AND THERAPY

Outcomes Associated with Apixaban Use in End-Stage Kidney Disease Patients with Atrial Fibrillation in the United States

(2018) Konstantinos C. Siontis et al.   CIRCULATION

Calciphylaxis

(2018) Sagar U. Nigwekar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study

(2018) Holger Reinecke et al.   BMJ Open

Dabigatran versus Warfarin in Patients with Mechanical Heart Valves

(2013) John W. Eikelboom et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trends in the Incidence of Atrial Fibrillation in Older Patients Initiating Dialysis in the United States

(2012) Benjamin A. Goldstein et al.   CIRCULATION

Incident Atrial Fibrillation and Risk of End-Stage Renal Disease in Adults With Chronic Kidney Disease

(2012) Nisha Bansal et al.   CIRCULATION

Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease

(2012) Jonas Bjerring Olesen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness and Safety of Warfarin Initiation in Older Hemodialysis Patients with Incident Atrial Fibrillation

(2011) W. C. Winkelmayer et al.   Clinical Journal of the American Society of Nephrology

The Intersection of Risk and Benefit

(2009) Manish M. Sood et al.   CHEST

Dilemmas in the Management of Atrial Fibrillation in Chronic Kidney Disease

(2008) H. Reinecke et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY